Lauren E McGrath
Overview
Explore the profile of Lauren E McGrath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gustafson T, McGrath L, Hayes M, Mietlicki-Baase E
Neurosci Res
. 2024 Oct;
212:136-139.
PMID: 39389183
The pancreatic peptide amylin promotes negative energy balance in part through activation of amylin receptors (AmyRs) expressed in the ventral tegmental area (VTA), but studies have been limited to male...
2.
Stein L, McGrath L, Lhamo R, Koch-Laskowski K, Fortin S, Skarbaliene J, et al.
Am J Physiol Regul Integr Comp Physiol
. 2021 Jul;
321(2):R250-R259.
PMID: 34259025
The peptide hormone amylin reduces food intake and body weight and is an attractive candidate target for novel pharmacotherapies to treat obesity. However, the short half-life of native amylin and...
3.
Liberini C, Koch-Laskowski K, Shaulson E, McGrath L, Lipsky R, Lhamo R, et al.
Sci Rep
. 2019 Jun;
9(1):8447.
PMID: 31186439
A growing appreciation of the overlapping neuroendocrine mechanisms controlling energy balance has highlighted combination therapies as a promising strategy to enhance sustained weight loss. Here, we investigated whether amylin- and...
4.
Mietlicki-Baase E, Liberini C, Workinger J, Bonaccorso R, Borner T, Reiner D, et al.
Diabetes Obes Metab
. 2018 Jan;
20(5):1223-1234.
PMID: 29327400
Aims: While pharmacological glucagon-like peptide-1 receptor (GLP-1R) agonists are FDA-approved for treating type 2 diabetes mellitus (T2DM) and obesity, a major side effect is nausea/malaise. We recently developed a conjugate...
5.
Chen X, Mietlicki-Baase E, Barrett T, McGrath L, Koch-Laskowski K, Ferrie J, et al.
J Am Chem Soc
. 2017 Nov;
139(46):16688-16695.
PMID: 29130686
Peptide hormones are attractive as injectable therapeutics and imaging agents, but they often require extensive modification by mutagenesis and/or chemical synthesis to prevent rapid in vivo degradation. Alternatively, the single-atom,...
6.
Reiner D, Leon R, McGrath L, Koch-Laskowski K, Hahn J, Kanoski S, et al.
Neuropsychopharmacology
. 2017 Sep;
43(3):627-637.
PMID: 28920591
The neurobiological substrates that mediate the anorectic effects of both endogenous glucagon-like peptide-1 (GLP-1) and exogenous GLP-1 receptor (GLP-1R) agonists are an active area of investigation. As the lateral dorsal...
7.
Mietlicki-Baase E, McGrath L, Koch-Laskowski K, Krawczyk J, Reiner D, Pham T, et al.
Neuropharmacology
. 2017 May;
123:67-79.
PMID: 28552704
Amylin is produced in the pancreas and the brain, and acts centrally to reduce feeding and body weight. Recent data show that amylin can act in the ventral tegmental area...
8.
Mietlicki-Baase E, Koch-Laskowski K, McGrath L, Krawczyk J, Pham T, Lhamo R, et al.
Physiol Behav
. 2017 Apr;
177:122-128.
PMID: 28433470
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from intestinal L-cells in response to food entering into the gastrointestinal tract. GLP-1-based pharmaceuticals improve blood glucose regulation and reduce feeding. Specific...
9.
Reiner D, Mietlicki-Baase E, Olivos D, McGrath L, Zimmer D, Koch-Laskowski K, et al.
Biol Psychiatry
. 2017 Feb;
82(11):828-838.
PMID: 28237459
Background: The pancreatic- and brain-derived hormone amylin promotes negative energy balance and is receiving increasing attention as a promising obesity therapeutic. However, the neurobiological substrates mediating amylin's effects are not...
10.
Mietlicki-Baase E, McGrath L, Koch-Laskowski K, Krawczyk J, Pham T, Lhamo R, et al.
Physiol Behav
. 2017 Jan;
173:9-14.
PMID: 28119159
The beneficial glycemic and food intake-suppressive effects of glucagon-like peptide-1 (GLP-1) have made this neuroendocrine system a leading target for pharmacological approaches to the treatment of diabetes and obesity. One...